8-K Announcements
6Material company update
Apr 6, 2026·SEC
Material company update
Apr 6, 2026·SEC
Material company update
Apr 1, 2026·SEC
Oncolytics Biotech Inc.(ONCY)Earnings, Financials & Key Ratios
ONCY•NASDAQ
$0.90
$97M mkt cap·Price updated May 7, 2026
AboutOncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Show more
- Revenue$0
- EBITDA-$35M-41.0%
- Net Income-$32M-54.2%
- EPS (Diluted)-0.41
- ROE-189.05%-148.5%
- Debt/Equity0.18+1058.8%
ONCY Key Insights
Oncolytics Biotech Inc. (ONCY) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 13.1% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 15.7x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ONCY Price & Volume
Oncolytics Biotech Inc. (ONCY) stock price & volume — 10-year historical chart
Loading chart...
ONCY Growth Metrics
Oncolytics Biotech Inc. (ONCY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-37.29%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-7.24%
Return on Capital
10 Years-107.2%
5 Years-85.58%
3 Years-91.06%
Last Year-145.51%
ONCY Recent Earnings
Oncolytics Biotech Inc. (ONCY) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
Mar 30, 2026EPS
$0.08
Est $0.06
-33.3%
Revenue
—
Q4 2025
Nov 12, 2025EPS
$0.10
Est $0.12
+16.7%
Revenue
—
Q3 2025
Aug 8, 2025EPS
$0.05
Est $0.11
+54.5%
Revenue
—
Q2 2025
May 14, 2025EPS
$0.06
Est $0.09
+33.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 30, 2026 | $0.08vs $0.06-33.3% | — |
| Q4 2025 | Nov 12, 2025 | $0.10vs $0.12+16.7% | — |
| Q3 2025 | Aug 8, 2025 | $0.05vs $0.11+54.5% | — |
| Q2 2025 | May 14, 2025 | $0.06vs $0.09+33.3% | — |
Based on last 12 quarters of dataView full earnings history →
ONCY Peer Comparison
Oncolytics Biotech Inc. (ONCY) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 CLDX | 2.22B | 33.32 | -8.54 | -78.63% | -172.53% | -41.68% | 0.00 | |
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 VVOS | 5.49M | 0.66 | -0.30 | 8.91% | -98.77% | -6.76% | 0.19 | |
 AMGN | 177.59B | 329.06 | 23.12 | 9.92% | 20.95% | 89.41% | 6.31 | |
 GILD | 166.4B | 134.06 | 19.77 | 2.4% | 30.99% | 42.33% | 1.09 | |
 RCUS | 2.5B | 24.80 | -7.54 | -4.26% | -156.36% | -68.97% | 0.16 | |
 AGEN | 132.45M | 3.75 | -1102.94 | 10.37% | 0.1% |
Compare ONCY vs Peers
Oncolytics Biotech Inc. (ONCY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ONCY Income Statement
Oncolytics Biotech Inc. (ONCY) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 162.23K | 90.77K | 95.38K | 485.57K | 332.65K | 360.57K | 301.11K | 298.59K | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -162.23K▲ 0% | -90.77K▲ 44.1% | -95.38K▼ 5.1% | -485.57K▼ 409.1% | -332.65K▲ 31.5% | -360.57K▼ 8.4% | -301.11K▲ 16.5% | -298.59K▲ 0.8% | 0▲ 100.0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | 10.08% | 44.05% | -5.08% | -409.12% | 31.49% | -8.39% | 16.49% | 0.84% | 100% | - |
| Operating Expenses | 15.29M | 15.61M | 16.66M | 20.69M | 18.65M | 20.56M | 20.38M | 24.74M | 34.98M | 34.98M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 5.36M | 6.21M | 7.08M | 8.84M | 9M | 10.26M | 8.53M | 11.62M | 13.34M | 15.31M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 9.77M | 9.39M | 9.42M | 11.13M | 9.65M | 10.31M | 11.85M | 13.12M | 21.65M | 18.96M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 162.23K | 0 | 0 | 9.56M | 0 | 0 | 0 | 0 | 0 | 708K |
| Operating Income | -15.29M▲ 0% | -15.61M▼ 2.0% | -16.66M▼ 6.8% | -20.69M▼ 24.2% | -18.98M▲ 8.3% | -20.93M▼ 10.2% | -20.68M▲ 1.2% | -25.04M▼ 21.1% | -34.98M▼ 39.7% | -34.98M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -9.89% | -2.03% | -6.77% | -24.19% | 8.28% | -10.25% | 1.17% | -21.06% | -39.73% | - |
| EBITDA | -15.13M | -15.51M | -16.57M | -20.21M | -18.65M | -20.56M | -20.38M | -24.74M | -34.88M | -34.6M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -10.15% | -2.53% | -6.78% | -21.97% | 7.72% | -10.28% | 0.9% | -21.38% | -41% | -5.31% |
| D&A (Non-Cash Add-back) | 162.23K | 90.77K | 95.38K | 485.57K | 332.65K | 360.57K | 301.11K | 298.59K | 102K | 382K |
| EBIT | -13.96M | -14.83M | -17.27M | -20.14M | -16.78M | -20.94M | -19.01M | -20.49M | -34.98M | -35.79M |
| Net Interest Income | 0 | 0 | 0 | 179.28K | 90.36K | 99K | 528K | 1.33M | 1.2M | 479K |
| Interest Income | 163.9K | 130.1K | 173.5K | 179.28K | 90.36K | 99K | 528K | 1.33M | 1.2M | 479K |
| Interest Expense | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 163.9K | 130.1K | 173.5K | -12.43M | 2.2M | -15.88K | 1.67M | 4.55M | 3.4M | -431K |
| Pretax Income | -15.13M▲ 0% | -15.48M▼ 2.3% | -16.49M▼ 6.6% | -33.12M▼ 100.9% | -16.78M▲ 49.3% | -20.94M▼ 24.8% | -19.01M▲ 9.2% | -20.49M▼ 7.8% | -31.58M▼ 54.1% | -35.41M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 9.37K | 141.5K | 548.04K | 0 | 0 | 39.42K | 64.52K | 71.87K | 130K | -144K |
| Effective Tax Rate % | -0.06% | -0.91% | -3.32% | 0% | 0% | -0.19% | -0.34% | -0.35% | -0.41% | 0.41% |
| Net Income | -15.14M▲ 0% | -15.62M▼ 3.1% | -17.04M▼ 9.1% | -45.55M▼ 167.4% | -16.78M▲ 63.2% | -20.98M▼ 25.0% | -19.08M▲ 9.1% | -20.56M▼ 7.8% | -31.71M▼ 54.2% | -35.27M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -10.33% | -3.15% | -9.1% | -167.37% | 63.17% | -25.05% | 9.08% | -7.79% | -54.22% | -37.29% |
| Net Income (Continuing) | -15.14M | -15.62M | -17.04M | -33.12M | -16.78M | -20.98M | -19.08M | -20.56M | -31.71M | -35.27M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.20▲ 0% | -1.12▲ 6.7% | -1.06▲ 5.4% | -2.06▼ 94.3% | -0.48▲ 76.7% | -0.49▼ 2.1% | -0.43▲ 12.2% | -0.41▲ 4.7% | -0.41▲ 0.0% | -0.35▲ 0% |
| EPS Growth % | -3.45% | 6.67% | 5.36% | -94.34% | 76.7% | -2.08% | 12.24% | 4.65% | 0% | -7.24% |
| EPS (Basic) | -1.20 | -1.12 | -1.06 | -2.06 | -0.48 | -0.49 | -0.43 | -0.41 | -0.41 | - |
| Diluted Shares Outstanding | 12.62M | 13.94M | 16.02M | 22.14M | 40.34M | 53.51M | 58.03M | 67.62M | 76.48M | 101.32M |
| Basic Shares Outstanding | 12.62M | 13.94M | 16.02M | 22.14M | 40.34M | 53.51M | 58.03M | 67.62M | 76.48M | 101.32M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ONCY Balance Sheet
Oncolytics Biotech Inc. (ONCY) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 14.44M | 17.82M | 14.45M | 18.93M | 33.74M | 44.9M | 35.68M | 38.17M | 18.88M | 14.05M |
| Cash & Short-Term Investments | 14.12M | 11.84M | 13.7M | 14.15M | 31.22M | 41.26M | 32.14M | 34.91M | 15.94M | 12.35M |
| Cash Only | 12.03M | 11.84M | 13.7M | 14.15M | 31.22M | 41.26M | 11.67M | 34.91M | 15.94M | 12.35M |
| Short-Term Investments | 2.09M | 0 | 0 | 0 | 0 | 0 | 20.47M | 0 | 0 | 0 |
| Accounts Receivable | 54.41K | 4.8M | 51.65K | 0 | 0 | 866K | 521K | 15K | 68K | 54K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 2.07M | 89.66K | 0 | 0 | 0 | 980K | 0 |
| Total Non-Current Assets | 319.95K | 333.44K | 412.74K | 727.48K | 609.13K | 976K | 1.65M | 647K | 1.31M | 1.01M |
| Property, Plant & Equipment | 319.95K | 333.44K | 412.74K | 727.48K | 609.13K | 976K | 652K | 647K | 1.31M | 1.01M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 998K | 0 | 0 | 0 |
| Total Assets | 14.76M▲ 0% | 18.15M▲ 23.0% | 14.87M▼ 18.1% | 19.66M▲ 32.2% | 34.35M▲ 74.7% | 45.88M▲ 33.6% | 37.33M▼ 18.6% | 38.82M▲ 4.0% | 20.19M▼ 48.0% | 15.06M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | -46.11% | 22.98% | -18.1% | 32.24% | 74.72% | 33.58% | -18.63% | 3.98% | -48% | -166.96% |
| Total Current Liabilities | 4.07M | 5.23M | 2.81M | 12.87M | 2.71M | 2.69M | 3.94M | 4.24M | 6.69M | 7.66M |
| Accounts Payable | 4.07M | 3.51M | 1.83M | 3.17M | 1.81M | 594K | 2.25M | 1.08M | 1.09M | 4.2M |
| Days Payables Outstanding | 9.15K | 14.1K | 6.99K | 2.39K | 1.98K | 601.29 | 2.73K | 1.32K | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 1.55M | 927.4K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 178.13K | 988.72K | 9.36M | 655.21K | 408K | 79K | 532K | 1.62M | 199K |
| Current Ratio | 3.55x | 3.41x | 5.13x | 1.47x | 12.45x | 16.69x | 9.05x | 9.01x | 2.82x | 2.82x |
| Quick Ratio | 3.55x | 3.41x | 5.13x | 1.47x | 12.45x | 16.69x | 9.05x | 9.01x | 2.82x | 2.82x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 4.64M | 5.86M | 6.9M | 6.88M | 7.09M | 6.89M | 7.02M | 7.52M | 7.29M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 166.43K | 153.17K | 361K | 157K | 290K | 787K | 2.65M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 5.86M | 6.73M | 6.73M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 4.07M | 9.87M | 8.67M | 19.77M | 9.59M | 9.78M | 10.83M | 11.26M | 14.2M | 14.94M |
| Total Debt | 0 | 0 | 0 | 506.27K | 402.06K | 655K | 373K | 423K | 1.06M | 835K |
| Net Debt | -12.03M | -11.84M | -13.7M | -13.64M | -30.82M | -40.61M | -11.29M | -34.49M | -14.88M | -11.52M |
| Debt / Equity | - | - | - | - | 0.02x | 0.02x | 0.01x | 0.02x | 0.18x | 0.18x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.02x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.33x |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 10.69M▲ 0% | 8.28M▼ 22.5% | 6.2M▼ 25.2% | -107.89K▼ 101.7% | 24.75M▲ 23042.0% | 36.1M▲ 45.8% | 26.5M▼ 26.6% | 27.56M▲ 4.0% | 5.98M▼ 78.3% | 115K▲ 0% |
| Equity Growth % | -56.68% | -22.51% | -25.21% | -101.74% | 23041.96% | 45.84% | -26.59% | 4% | -78.29% | -315.5% |
| Book Value per Share | 0.85 | 0.59 | 0.39 | -0.00 | 0.61 | 0.67 | 0.46 | 0.41 | 0.08 | 0.00 |
| Total Shareholders' Equity | 10.69M | 8.28M | 6.2M | -107.89K | 24.75M | 36.1M | 26.5M | 27.56M | 5.98M | 115K |
| Common Stock | 262.32M | 271.71M | 285.19M | 311.08M | 356.82M | 391.35M | 404.04M | 430.91M | 438.19M | 458.63M |
| Retained Earnings | -278.83M | -294.45M | -311.48M | -344.61M | -367.11M | -393.42M | -418.25M | -446M | -477.71M | -504.96M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 554.06K | 373.73K | 607.5K | 4.08M | 4.02M | 388K | 662K | 544K | 961K | 789K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ONCY Cash Flow Statement
Oncolytics Biotech Inc. (ONCY) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.48M | -14.89M | -11.92M | -19.91M | -22.07M | -22.43M | -23.36M | -28.45M | -26.97M | -26.97M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 17.01% | -19.34% | 19.95% | -66.99% | -10.86% | -1.66% | -4.11% | -21.81% | 5.21% | -33% |
| Net Income | -15.14M | -15.62M | -17.04M | -33.12M | -22.51M | -26.3M | -24.84M | -27.75M | -31.71M | -35.27M |
| Depreciation & Amortization | 162.23K | 90.77K | 95.38K | 485.57K | 446.19K | 452.06K | 392K | 403K | 424K | 382K |
| Stock-Based Compensation | 406.08K | 578.7K | 1.42M | 1.47M | 2.56M | 3.83M | 2.38M | 2.07M | 2.72M | 7.04M |
| Deferred Taxes | -545.89K | 0 | -374.34K | 12.96M | -2.85M | 408.56K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 406.08K | -124.79K | 75.78K | 94.82K | 68.53K | 91.73K | -1.68M | -4.93M | -1.94M | 818K |
| Working Capital Changes | 2.23M | 180.85K | 3.9M | -1.8M | 209.78K | -907.99K | 391K | 1.76M | 3.54M | 558K |
| Change in Receivables | 285.65K | -4.77M | 4.77M | -2.02M | 1.98M | -776.39K | 345K | 506K | -53K | 14K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -51.35K | 1.98M | -107.47K | -10.9K | -29.3K | -285.95K | -20.4M | 20.22M | -239K | -13K |
| Capital Expenditures | -23.53K | -105.77K | -107.47K | -10.9K | -29.3K | -285.95K | -55K | -8K | -239K | -13K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -28 | 2.09M | 0 | 0 | 0 | 0 | -20.35K | 0 | 0 | 0 |
| Cash from Financing | 956.13K | 12.81M | 13.3M | 21.02M | 39.77M | 33.02M | 12.21M | 31.99M | 6.64M | 18.74M |
| Debt Issued (Net) | 0 | 0 | 0 | -447.5K | -461K | -366K | -381K | -407K | -348K | -406K |
| Equity Issued (Net) | 956.13K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 4M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 343.44K | 124.95K | 3.47M | 1.94M | 469.68K | 12K | 781K | 65K | 0 |
| Net Change in Cash | -11.98M▲ 0% | -198.16K▲ 98.3% | 1.86M▲ 1040.5% | 448.14K▼ 76.0% | 17.07M▲ 3709.4% | 10.04M▼ 41.2% | -29.6M▼ 394.7% | 23.25M▲ 178.5% | -18.97M▼ 181.6% | -7.25M▲ 0% |
| Free Cash Flow | -12.5M▲ 0% | -15M▼ 20.0% | -12.03M▲ 19.8% | -19.92M▼ 65.6% | -22.1M▼ 10.9% | -22.72M▼ 2.8% | -23.41M▼ 3.0% | -28.46M▼ 21.6% | -27.2M▲ 4.4% | -26.48M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 17.45% | -19.97% | 19.8% | -65.59% | -10.95% | -2.82% | -3.04% | -21.55% | 4.4% | -3.92% |
| FCF per Share | -0.99 | -1.08 | -0.75 | -0.90 | -0.55 | -0.42 | -0.40 | -0.42 | -0.36 | -0.36 |
| FCF Conversion (FCF/Net Income) | 0.82x | 0.95x | 0.70x | 0.44x | 1.32x | 1.07x | 1.22x | 1.38x | 0.85x | 0.75x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 136.16K | 15.73K | 5.45K | 12K | 35K | 46K | 120K | 184K | 0 |
ONCY Key Ratios
Oncolytics Biotech Inc. (ONCY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -85.62% | -164.62% | -235.33% | -1496.6% | -136.16% | -68.96% | -60.95% | -76.06% | -189.05% | -755.18% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | -289.9% | -453.39% | - | 293.51% |
| Debt / Equity | - | - | - | - | 0.02x | 0.02x | 0.01x | 0.02x | 0.18x | 0.18x |
| FCF Conversion | 0.82x | 0.95x | 0.70x | 0.44x | 1.32x | 1.07x | 1.22x | 1.38x | 0.85x | 0.75x |
ONCY SEC Filings & Documents
Oncolytics Biotech Inc. (ONCY) SEC filings — annual & quarterly reports (10-K, 10-Q)
10-K Annual Reports
1FY 2026
Mar 30, 2026·SEC
ONCY Frequently Asked Questions
Oncolytics Biotech Inc. (ONCY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Oncolytics Biotech Inc. (ONCY) grew revenue by 0.0% over the past year. Growth has been modest.
Oncolytics Biotech Inc. (ONCY) reported a net loss of $35.3M for fiscal year 2024.
Dividend & Returns
Oncolytics Biotech Inc. (ONCY) has a return on equity (ROE) of -189.1%. Negative ROE indicates the company is unprofitable.
Oncolytics Biotech Inc. (ONCY) had negative free cash flow of $26.5M in fiscal year 2024, likely due to heavy capital investments.
Explore More ONCY
Oncolytics Biotech Inc. (ONCY) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates